Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | MAX | P61244 | 1/20 | 0.37 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656280 | 0.87 | KMT2A (0.52) | TSHRKMT2AXDHHIF1AALOX15 | |
| SCHEMBL19330159 | 0.86 | MAPT (0.49) | TSHRKMT2AXDHHIF1AALOX15 | |
| SCHEMBL2657835 | 0.80 | KDM4E (0.55) | TSHRKMT2AHIF1AALOX15RXRA | |
| SCHEMBL1424832 | 0.79 | MAPT (0.47) | TSHRKMT2AXDHHIF1AALOX15 | |
| SCHEMBL2658290 | 0.78 | KMT2A (0.43) | TSHRKMT2AXDHHIF1AALOX15 | |
| SCHEMBL9070865 | 0.76 | SMN1; SMN2 (0.50) | GCKKMT2A | |
| SCHEMBL20944369 | 0.74 | KDM4E (0.47) | TSHRKMT2AHIF1AALOX15RXRA | |
| SCHEMBL4276418 | 0.73 | PLA2G2A (0.54) | RARARARBRARGGCKNR1H4 | |
| SCHEMBL17060023 | 0.73 | NR1H4 (0.54) | RARARARBRARGGCKNR1H4 | |
| SCHEMBL19543017 | 0.73 | KDM4E (0.40) | KMT2ARXRARXRBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| CN-106279283-A | Novel activators of glucokinase | 症变治疗公司 | 2017-01-04 | — | — | CN | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| CN-101821276-B | Novel glucokinase activators | 症变治疗公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-8940927-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2185570-B1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2185570-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | Metabasis Therapeutics, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | RARA 4038/4885RARB 4520/4885RARG 4435/4885 |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | RARA 3930/4885RARB 4546/4885RARG 4518/4885 |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | RARA 3930/4885RARB 4546/4885RARG 4518/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | RARA 3930/4885RARB 4546/4885RARG 4518/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | RARA 3781/4885RARB 4444/4885RARG 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.